QIAGEN N.V. Files 2024 Annual Report
Ticker: QGEN · Form: 20-F · Filed: Mar 31, 2025 · CIK: 1015820
| Field | Detail |
|---|---|
| Company | Qiagen N.V. (QGEN) |
| Form Type | 20-F |
| Filed Date | Mar 31, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, financials, sec-filing
TL;DR
QIAGEN dropped its 2024 20-F, check the financials.
AI Summary
QIAGEN N.V. filed its 20-F annual report for the fiscal year ending December 31, 2024. The report details the company's financial performance and business operations. Key financial data and operational highlights are presented within the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of QIAGEN's financial health and strategic direction for the past fiscal year.
Risk Assessment
Risk Level: low — This is a standard annual financial filing with no immediate red flags.
Key Numbers
- 2024 — Fiscal Year (The period covered by the 20-F filing.)
- 1231 — Fiscal Year End (Indicates the end of the reporting period.)
Key Players & Entities
- QIAGEN N.V. (company) — Filer of the 20-F report
- 20241231 (date) — Fiscal year end date
- 20250331 (date) — Filing date
FAQ
What is the primary business of QIAGEN N.V.?
QIAGEN N.V. is primarily involved in the biological products sector, specifically excluding diagnostic substances, as indicated by its SIC code [2836].
When was the 20-F filing submitted?
The 20-F filing was submitted on March 31, 2025.
What is the fiscal year end for QIAGEN N.V.?
QIAGEN N.V.'s fiscal year ends on December 31st.
What is the company's primary address?
The company's business and mail address is Hulsterweg 82, Venlo, P7, 5912.
What is the SEC file number for QIAGEN N.V.?
The SEC file number for QIAGEN N.V. is 001-38332.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on March 31, 2025 regarding QIAGEN N.V. (QGEN).